💰 280E Bets, 11.5% Money, And Ballot Blowback

Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.

Today’s briefing focuses on pressure points that are no longer theoretical: operators betting early on 280E relief, capital markets charging 11.5 percent for runway, and ballot campaigns where money and messaging matter as much as policy. We also track how rescheduling remains procedurally fragile, why hemp and CBD enforcement keeps tightening, and where states are quietly expanding access while regulators catch up.

Today’s edition is supported by Wispr Flow and The Rundown AI.
To sponsor Policy, Decoded and reach the executives, investors, and policymakers who read this briefing, reply to this email and we will send details.

💰 Tax Risk Meets Reality
🏦 Capital Still Costs
🗳️ Ballot Politics Get Expensive

The price of waiting is rising.

New this week: Policy, Decoded now delivers Quick Briefs and Sidebars daily, with a deeper Read-In every Sunday morning. If you know someone who should be reading this, share the email. Referrals earn swag.

💰 280E Filings Move From Talk To Real Audit Exposure

Some operators and advisers are filing as if 280E already does not apply, even though cannabis remains Schedule I and DOJ has not finalized rescheduling. The argument leans on the government’s own posture and the view that the classification is collapsing in practice, even if the rule has not landed. The IRS risk stays clean: audit exposure, penalties, and years of cost if the position fails. I hope any firm telling clients to take this position is well insured and has put every material risk in writing, because assuming the federal government will behave predictably has a long track record of disappointment. THC Group is not among those recommending this approach. (Outlaw Report)

🗳️ Ted Budd Challenges Rescheduling After Speaking With Trump

Senator Ted Budd says he raised concerns directly with President Trump that the administration was poorly advised on marijuana rescheduling. Budd is attacking the public case for Schedule III, arguing research benefits are overstated and the move collides with FDA’s role in drug approval. The more important point for executives is process volatility, because a senator can walk away with a conclusion and the administration can still pivot as lawyers, agencies, and politics collide. Coalition dissent extends timelines and feeds litigation narratives before DOJ has even finished the paperwork. If your planning assumes near-term tax relief and insurance shifts, budget for delay and for a process that gets stress-tested in public. (Marijuana Moment)

🏦 Curaleaf Buys Time With A $500 Million Refinance At 11.5%

Curaleaf raised $500 million in a private placement and pushed its maturity horizon to February 1, 2029. The notes carry an 11.5% rate and the proceeds refinance senior secured notes previously due this December. The headline is runway, and the subtext is price, because even the biggest names still pay a premium for duration. Curaleaf also keeps investors guessing on strategy, all in on hemp until it is not, eyeing West Coast expansion until it is not, and that pattern makes this feel like positioning for optionality. Higher fixed costs narrow the margin for operational misses and tighten the leash on every growth narrative. (MJBizDaily)

🌍 Canadian Cannabis Eyes Exports, And U.S. Operators Should Pay Attention

Canadian producers are increasingly looking to international markets as high domestic taxes, price compression, and retail saturation keep margins thin at home. StratCann describes exports as a pressure valve, with medical channels in Europe, Australia, and Israel offering better pricing discipline than Canada’s crowded retail shelves. The structural irony is that Canada built scale early, then regulated and taxed it into a low-margin grind, so the smartest players look for higher-value outlets. For U.S. executives gaming out interstate commerce, the bigger competitive threat may sit north of the border, because Canada has production capacity, quality controls, and a compliance culture built for cross-border trade. If federal policy ever allows import, even in a narrow medical lane, Canada is positioned to move fast, and domestic operators will learn what real price competition feels like. (StratCann)

💸 Massachusetts Repeal Bid Runs On A National Playbook And One Check

The committee trying to end adult-use cannabis sales in Massachusetts raised $1.55 million last year from a single out-of-state donor. The funding came from SAM Action Inc., a national anti-legalization group that does not disclose its donors, and it is enough to power signatures and messaging. The larger story is the broader SAM playbook, aggressive spend and a willingness to blur categories so gas station hemp products get treated as if they were the regulated adult-use market. That approach feeds moral panic language and headline terms like scromiting that spread faster than nuance. If this qualifies, the contest shifts from policy merits into trust, transparency, and whether voters accept a repeal push financed through a black box. (The Inquirer and Mirror)

📰 NYT Board Reopens The Weed Debate With A Self-Congratulating Pivot

The New York Times editorial board is reaffirming legalization while delivering a long lecture on harms, framed around public smell, potency, daily use, addiction, and emergency room stories. The tone carries a quiet victory lap, we supported legalization early, before pivoting into familiar talking points, including reviving Maureen Dowd’s Colorado edible episode as a cultural shorthand. Their preferred fix is heavier regulation through taxes, including potency-based taxation, plus tighter marketing limits and skepticism toward broad medical claims. What is missing is accountability for the policy failures that made the rough edges predictable: public education has been underfunded, and states have offered few credible incentives or pathways to convert illicit operators into the licensed system. When mainstream voices frame legalization as the problem while ignoring the implementation choices, they hand ammunition to repeal campaigns and invite blunt regulation that hits compliant businesses first. (New York Times Opinion)

🗳️ Ohio Referendum Effort Faces A Money Race And A Voter Education Race

Ohioans for Cannabis Choice is pushing a veto referendum to block key parts of Senate Bill 56, the package that rewrote elements of the voter-approved adult-use law and tightened the intoxicating hemp lane. Attorney General Dave Yost approved the revised title and summary, clearing the procedural gate for signature gathering after an earlier rejection. The steepest climb now is money, because signature operations at this scale are expensive and the campaign also has to teach voters what a veto referendum vote means and how to cast it. All of that runs against the same clock as looming federal hemp changes that could scramble the intoxicant landscape before Ohio settles its own politics. Ohio’s governor has not exactly shown patience for complaints, and that tone matters when campaigns need friendly oxygen. (WKYC)

⚖️ Virginia Retail Bill Advances As Senate Adds Tougher Penalties

Virginia’s push to finally stand up an adult-use retail market is moving, and the Senate is also layering in harsher criminal penalties that are splitting Democrats. Committee amendments championed by Sen. Scott Surovell raise illegal sales penalties, add consequences for buying from unlicensed sellers, and move underage possession closer to alcohol-style misdemeanor treatment, all aimed at creating real incentives to enter the licensed market. Reform advocates are warning that this edges back toward recriminalization, especially for youth and low-level conduct that was intentionally de-escalated in prior reforms. The policy trade is the point: lawmakers want a regulated marketplace with enforcement gravity, and they are debating how much of that gravity should fall on consumers versus sellers. Executives watching Virginia should read this as a signal that the state wants order and compliance at launch, and the political risk is that penalties become the story that slows consensus just when the governor’s posture finally changed. (Ganjapreneur)

🏥 Beshear Pushes A Big Eligibility Expansion With National Politics In The Background

Governor Andy Beshear is urging lawmakers to add 16 qualifying conditions to Kentucky’s medical cannabis law, saying it could expand eligibility to about 430,000 Kentuckians. The timing is intentional: eligibility defines market size, license economics, and access expectations before the program fully stands up. This also reads as good politics for a governor with national ambition, because expanding access is popular and frames the issue around patients rather than industry. The risk is procedural sabotage by proxy, where condition fights become a way to slow implementation without saying so. If the list expands, regulators and licensees will need clean clinical guardrails and documentation discipline to avoid backlash. (Lexingtonky.news)

🧑‍💼 New Jersey’s Workplace Fix Is Written. Agencies Own The Outcome.

Former New Jersey Cannabis Regulatory Commission vice chair Sam Delgado says Bill S4847 resolved key workplace ambiguity and the remaining work is execution. His core point is practical: a positive cannabis test does not establish impairment, and employers need a defensible process built on observable behavior and documentation. Moving WIRE into the Department of Labor aligns it with statewide training infrastructure and keeps it out of a law-enforcement frame. The hinge now is rules and scale: final standards, approved providers, and real training throughput. Slow implementation leaves employers stuck in the same litigation fog, only with a revised statute hanging over the conversation. (NJ Advance Media)

🍯 EFSA’s CBD Intake Limit Forces Dose Math Into U.S. Terms

Europe’s food safety authority set a provisional safe intake level for CBD in food at 0.0275 mg per kilogram of body weight per day. In U.S. terms, that is about 0.0125 mg per pound per day, roughly 2 mg per day for a 154-pound adult. EFSA says it applied added caution due to incomplete long-term evidence and uncertainty around liver effects and other systems. It also excludes sensitive groups, including people under 25, pregnant or breastfeeding women, and people taking medication. That combination tightens the box for ingestible CBD, especially products marketed for everyday use, and it sharpens the compliance pressure on serving size, claims, and enforcement consistency. (Reuters)

Retail Stores Track With Rising Cannabis And Tobacco Co-Use

A new analysis of CDC Behavioral Risk Factor Surveillance System data across 38 states from 2016 to 2023 links recreational legalization and licensed retail openings with higher cannabis use and higher co-use with tobacco. After legalization, sole cannabis use and concurrent use rose while sole tobacco use fell, and the start of retail sales aligned with additional increases in cannabis use and co-use. The study flags growth in groups with historically lower recreational use, including older adults and people with higher education, and it was pronounced among adults reporting poor mental health. For regulators and employers, this lands as a safety and impairment issue that resists simple screening shortcuts. Public health messaging also gets harder, because substitution narratives break when some consumers add cannabis to nicotine rather than replace it. (MedicalXpress)

🚨 Berks County Hemp Case Shows Why Labels And Licenses Have To Mean Something

Berks County District Attorney John Adams says lab testing confirmed two stores sold marijuana while representing it as hemp. The reporting I saw did not specify the exact lab results or how far over the legal threshold the products tested, and that detail matters because barely hot product and blatantly illegal product carry different policy implications. Either way, the case underscores why hemp needs enforceable testing standards, label accuracy, and licenses that can be revoked when sellers misrepresent what is on the shelf. Retailers and wholesalers who rely on paper COAs without verification are gambling with criminal exposure and reputational damage. Each confirmed case also pressures Harrisburg, because statewide rules look cleaner than county-by-county crackdowns. (Reading Eagle)

🌲 Illicit Cultivation Cleanup Looks Different When You Compare It To Superfund Scale

California’s public lands keep absorbing the environmental cost of illicit cultivation long after raids end. Reporting and field work describe pesticides, fertilizers, plastics, and other contaminants lingering in soil and waterways for months to years, with roughly 7,000 abandoned grow sites cataloged on public lands and only 587 known to have received at least partial cleanup. State wildlife crews have removed major debris loads, while federal land managers describe thin funding and staffing for hazardous remediation. It is worth keeping perspective: the country has lived through far larger industrial harms that poisoned water supplies and produced Superfund sites, and that does not excuse this problem, it clarifies the scale. The fix still comes back to steady funding, sustained cleanup capacity, and enforcement that prevents the next site from becoming tomorrow’s invoice. (CalMatters)